Platelets

Cost-Effectiveness of the INTERCEPT Blood System

for Platelets 

Many countries have approved incremental reimbursement for pathogen-inactivated platelets, including Switzerland and Belgium. In addition, the INTERCEPT™ Blood System for platelets allows hospitals to save costs by:

• Reducing the frequency of adverse events
• Reducing the need to transfuse expensive single donor platelets
• Eliminating the need for gamma-irradiated platelets
• Eliminating the need to purchase CMV negative platelets
• Not having to introduce secondary point of release testing

In the US reimbursement for outpatient hospital billing of pathogen-reduced platelets has been approved in 2015.